10X Genomics, Inc. current report, 10 December 2019

Full document

10x Genomics, Inc. — Form 8-K Summary

Business context and reporting period

10x Genomics filed a Current Report on Form 8-K dated December 10, 2019, under Item 7.01 (Regulation FD Disclosure). The filing concerns the company’s ongoing patent dispute with Bio-Rad Laboratories, Inc. and Lawrence Livermore National Security, LLC before the U.S. International Trade Commission (ITC). It is not a periodic financial report.

Financial metrics and liquidity

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.

Material changes versus the prior comparable period

  • The ITC extended the target date for completion of its investigation to December 12, 2019.
  • A Final Determination was therefore expected on or before December 12, 2019.

Litigation, risks, and unusual items

  • Bio-Rad and Lawrence Livermore filed the ITC action in July 2017, alleging that substantially all of 10x Genomics’ products infringed five U.S. patents.
  • The presiding judge’s September 2018 Initial Determination found that 10x Genomics’ GEM microfluidic chips directly infringed three patents: U.S. Patent Nos. 9,500,664, 9,636,682, and 9,649,635.
  • The Initial Determination found no infringement by the gel bead manufacturing microfluidic chip and Next GEM microfluidic chip on the claims at issue, and recommended an exclusion order and cease-and-desist order relating to imported GEM microfluidic chips.
  • The ITC was reviewing additional findings concerning alleged indirect infringement and claims involving the gel bead manufacturing and Next GEM microfluidic chips. The filing does not disclose the ultimate outcome or any financial impact.
  • An adverse Final Determination could potentially restrict imports or sales of affected products, but the filing does not quantify the operational or financial consequences.

Important facts for investors to verify

  • The ITC’s Final Determination issued on or before December 12, 2019.
  • Whether any exclusion order or cease-and-desist order was entered and which products or patent claims it covered.
  • Any subsequent appeals, settlements, licensing arrangements, or changes to the company’s product portfolio.
  • Any financial statement disclosures regarding contingencies, litigation costs, revenue exposure, or liquidity impacts.